Silence Therapeutics Plc ADR Down 4.67% To $24.69 After Earnings

Silence Therapeutics Plc ADR (SLN) said before open Wednesday that it lost $0.13 per share in quarter four 2023. The company reported $2.1 million in revenue

In the same quarter a year ago, the company lost $0.15 per share on revenue of $5.6 million.

The stock is down 4.67% to $24.69 after the report.

Silence Therapeutics Plc ADR's revenues declined at a faster pace than earnings.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Silence Therapeutics Plc ADR has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 99, putting Silence Therapeutics Plc ADR in the top 25% of stocks. The firm was recently trading at a 52-week high of $26.83 on March 8, 2024 and set a 52-week low on April 25, 2023 at $4.55.

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany.